Robins Global News & Noticias

  • Gaming Chair Review
    Gaming Chair Review
  • IT Career News
    IT Career News
  • Microsoft Exam
    Microsoft Exam
  • Youtube Marketing Guide
    Youtube Marketing Guide
  • Slot Game Review
    Slot Game Review
  • All Elite Wrestling
    All Elite Wrestling

RobinsPost News Network

+ Larger Font | - Smaller Font

Globe NewsWire News Distribution Service

Press Release: Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results

NDA (New Drug Application) and Marketing Authorization Application (MAA) completed in February 2020
Commercial readiness activities in U.S. underway for potential launch of PEDMARKTM, if approved, in the second half of 2020
Solid financial position with $13.7 million and no debt and the option to access $12.5 million in debt financing upon NDA approval of PEDMARK

RESEARCH TRIANGLE PARK, N.C., Feb. 14, 2020 (GLOBE NEWSWIRE) -- Fennec Pharmaceuticals Inc. (Nasdaq: FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today reported its business update and financial results for the fiscal year ended December 31, 2019.

"Fennec made great progress in 2019 preparing for some important milestones in 2020 including the recent announcement of regulatory submissions in both the U.S. and EU for PEDMARK” said Rosty Raykov, chief executive officer of Fennec. "During the year we also made solid progress in preparing for the potential launch of PEDMARK including the hiring of a chief commercial officer and the preparation and execution of our commercial readiness plan. We look forward to a number of significant milestones throughout 2020. If PEDMARK is granted a Priority Review, the Prescription Drug User Fee Act (PDUFA) action date is expected in the third quarter of 2020.”

Financial Results for the Fourth Quarter 2019

  • Cash Position - Cash and cash equivalents were $13.7 million as of December 31, 2019. The reduction in cash balance over the fiscal year is the result of cash used for operating activities including regulatory expenses associated with the regulatory submissions of PEDMARK and expenses associated with commercial launch preparation.
  • Research and Development (R&D) Expenses – R&D expenses were $1.2 million and $5.6 million, respectively, for the fourth quarter and year ended December 31, 2019, compared to $1.7 million and $5.0 million for the same period in 2018. The Company completed a significant part of the activities needed for regulatory approval of PEDMARK during the fourth quarter of 2019.
  • General and Administrative (G&A) Expenses – G&A expenses were $2.5 million and $7.4 million, respectively, for the fourth quarter and year ended December 31, 2019, compared to $1.4 million and $5.4 million, respectively for the same periods in 2018.  Fourth quarter increase in G&A was largely attributable to the commercialization efforts as the Company prepares to bring PEDMARK, if approved, to market in the second half of 2020. An additional increase in G&A expenses is attributed to a small rise in compensation to officers, directors and key contract employees in fiscal 2019 as compared to fiscal 2018. Shareholders passed a motion to increase the duration of all outstanding option contracts to a total of 10 years in 2019. This added $1.3 million in G&A in non-cash compensation over the prior year. Sales and marketing expenses increased by $0.4 million over the prior year as the Company began to focus efforts to commercialize PEDMARK. The company incurred approximately $0.25 million in additional administrative expenses as it added positions to the commercial team including the addition of a Chief Commercial Officer.
  • Net Loss - Net losses for the fourth quarter and year ended December 31, 2019 of $3.6 million ($0.18 per share) and $12.8 million ($0.64 per share), respectively, compared to $3.0 million ($0.15 per share) and $9.9 million ($0.52 per share), respectively, for the same periods in 2018.
  • Financial Guidance - The Company believes its cash and cash equivalents on hand as of December 31, 2019, along with the $12.5 million loan facility available upon FDA approval of PEDMARKTM will be sufficient to fund the Company's planned commercial launch of PEDMARKTM in the second half of 2020.

Financial Update

The selected financial data presented below is derived from our unaudited condensed consolidated financial statements which were prepared in accordance with U.S. generally accepted accounting principles. The complete audited condensed consolidated financial statements for the period ended December 31, 2019 and management's discussion and analysis of financial condition and results of operations will be available via and  All values are presented in thousands unless otherwise noted.

Audited Condensed Consolidated
Statement of Operations:
(U.S. Dollars in thousands except per share amounts)

 Three Months Ended  Twelve Months Ended 
 December 31,  December 31,  December 31,  December 31, 
 2019  2018  2019  2018 
Revenue$-  $-  $-  $- 
Operating expenses:               
Research and development 1,172   1,723   5,607   5,008 
General and administrative 2,481   1,382   7,402   5,401 
Loss from operations (3,653)  (3,105)  (13,009)  (10,409)
Other (expense)/income               
Unrealized gain/(loss) on derivatives -   -   -   167 
Amortization expense (18)  -   (64)  - 
Other loss (8  6   (17  6 
Net interest income 69   115   315   348 
Total other (expense)/income, net 43   121   234   521 
Net income/(loss)$(3,610) $(2,984) $(12,775) $(9,888)
Basic net income/(loss) per common share$(0.18) $(0.15) $(0.64) $(0.52)
Diluted net income/(loss) per common share$(0.18) $(0.15) $(0.64) $(0.52)
Fennec Pharmaceuticals Inc.
Balance Sheets
(U.S. Dollars in thousands)
 December 31, 2019 December 31, 2018
Cash and cash equivalents$13,650 $22,781
Other current assets 234  169
Non-current assets, net 262  -
Total Assets$14,146 $22,950
Liabilities and stockholders’ equity     
Current liabilities$2,271  $1,637
Total stockholders’ equity 11,875  21,313
Total liabilities and stockholders’ equity$14,146 $22,950
Working CapitalFiscal Year Ended 
Selected Asset and Liability Data:December 31, 2019  December 31, 2018 
(U.S. Dollars in thousands)     
Cash and cash equivalents$13,650  $22,781 
Other current assets 234   169 
Current liabilities excluding derivative liability (2,271)  (1,637)
Working capital$11,613  $21,313 
Selected Equity:       
Common stock & APIC$154,663  $151,326 
Accumulated deficit (144,031)  (131,256)
Stockholders’ equity 11,875   21,313 

Forward looking statements

Except for historical information described in this press release, all other statements are forward-looking. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including such risks that regulatory and guideline developments may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2019. Fennec Pharmaceuticals, Inc. disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at and

About PEDMARK™ (Sodium Thiosulfate (STS))

Cisplatin and other platinum compounds are essential chemotherapeutic agents for many pediatric malignancies. Unfortunately, platinum-based therapies cause ototoxicity, or hearing loss, which is permanent, irreversible and is particularly harmful to the survivors of pediatric cancer.

In the U.S. and Europe, it is estimated annually that over 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

PEDMARK has been studied by cooperative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, The Clinical Oncology Group Protocol ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled one of five childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, and medulloblastoma. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc., is a specialty pharmaceutical company focused on the development of PEDMARK for the prevention of platinum-induced ototoxicity in pediatric patients. PEDMARK received Breakthrough Therapy and Fast Track Designation by the FDA in March 2018.  Further, PEDMARK has received Orphan Drug Designation in the U.S. for this setting. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to STS and its use for chemoprotection, including the prevention of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit

For further information, please contact:

Rosty Raykov
Chief Executive Officer
Fennec Pharmaceuticals Inc.
T: (919) 636-5144

Elixir Health Public Relations
Lindsay Rocco
+1 862-596-1304
This email address is being protected from spambots. You need JavaScript enabled to view it.

Posted: 2020-02-14 11:00:00

Get Full News Story On GlobeNewsWire Press Release Service

Listen to this article. Speaker link opens in a new window.
Text To Speech BETA Test Version.

Print Friendly and PDF

Related News Stories From The Web And More

Related Bing News

Press Release: Fennec Provides Business Update and Announces Fiscal Year 2019 Financial Results | Globe NewsWire News Distribution Service | RobinsPost News Network - Newscast

Atlantica to Present Fiscal Year 2019 Financial Results on February 27

Fri, 21 Feb 2020 10:47:00 GMT

Atlantica to Present Fiscal Year 2019 Financial Results on February 27 February 21, 2020 – Atlantica Yield (NASDAQ: AY), the sustainable infrastructure company that owns a.

Precision BioSciences to Report Fiscal Year and Fourth Quarter 2019 Financial Results and Present at Upcoming Investor Conferences

Fri, 21 Feb 2020 04:00:00 GMT

DURHAM, N.C., Feb. 21, 2020 (GLOBE NEWSWIRE) -- Precision BioSciences, Inc. (Nasdaq: DTIL), a life sciences company dedicated to improving life through the application of its pioneering, proprietary ...

Ruth’s Hospitality Group, Inc. Reports Fourth Quarter and Fiscal Year 2019 Financial Results

Fri, 21 Feb 2020 04:00:00 GMT

WINTER PARK, Fla.--(Business Wire)--Ruth’s Hospitality Group, Inc. (the “Company”) (NASDAQ: RUTH) today reported unaudited financial results for its fourth quarter and fiscal year ended December 29, ...

VolitionRx Limited Announces Full Fiscal Year 2019 Financial Results and Business Update

Thu, 20 Feb 2020 16:50:00 GMT

Mr. Reynolds added "We strengthened our balance sheet throughout 2019 with existing investors exercising over $16 million ... I, along with the rest of the Board and indeed the whole company, look ...

AXT, Inc. Announces Fourth Quarter and Fiscal Year 2019 Financial Results

Wed, 19 Feb 2020 16:40:00 GMT

FREMONT, Calif., Feb. 19, 2020 -- AXT, Inc. (NasdaqGS: AXTI), a leading manufacturer of compound semiconductor substrates, today reported financial results for the fourth.

Related News Story Videos From Youtube

  • This Service Is Coming Soon.

  • Blow Us A Whistle

    Comments (Whistles) Designed By Disqus

    Company Information

    Official Content Providers


    We recommend Firefox 3 (and above), Edge, and Chrome for dynamic performance.
    © 2008-2020 RobinsPost (The Bird's Eye View Company) All rights are reserved.
    RobinsPost provides links to news sites based on their RSS feeds.
    All trademarks, copyrights, videos, photos and logos are owned by news sources.
    News stories, videos and live streams are from trusted sources:
    Bing News, Google News, Faroo News, and YouTube Search Results.
    ROBINSPOST Is Proudly Made In America.
    Where Quality, Safety and Service Comes First.